argenx SE (NASDAQ:ARGX) Shares Bought by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. grew its holdings in argenx SE (NASDAQ:ARGX) by 55.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,315 shares of the company’s stock after acquiring an additional 470 shares during the quarter. Daiwa Securities Group Inc.’s holdings in argenx were worth $712,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Profund Advisors LLC lifted its position in argenx by 3.0% during the 2nd quarter. Profund Advisors LLC now owns 973 shares of the company’s stock worth $418,000 after acquiring an additional 28 shares during the period. Raymond James Trust N.A. lifted its holdings in shares of argenx by 6.0% during the third quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock worth $268,000 after purchasing an additional 28 shares during the period. Wealth Alliance increased its holdings in argenx by 4.8% in the 2nd quarter. Wealth Alliance now owns 628 shares of the company’s stock worth $270,000 after buying an additional 29 shares during the period. GAMMA Investing LLC raised its position in argenx by 51.3% during the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after buying an additional 40 shares during the last quarter. Finally, Sequoia Financial Advisors LLC raised its position in argenx by 3.1% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company’s stock worth $737,000 after buying an additional 52 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ARGX shares. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “buy” rating to a “hold” rating in a research note on Friday, October 4th. JPMorgan Chase & Co. lifted their price objective on argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. Scotiabank upgraded argenx from a “sector perform” rating to a “sector outperform” rating and upped their target price for the stock from $439.00 to $715.00 in a research note on Tuesday, November 5th. Truist Financial lifted their price target on argenx from $540.00 to $660.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, JMP Securities upped their price objective on argenx from $497.00 to $606.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $630.42.

argenx Price Performance

NASDAQ ARGX opened at $616.55 on Friday. The stock’s 50 day simple moving average is $565.73 and its 200-day simple moving average is $496.24. The company has a market cap of $37.22 billion, a PE ratio of -700.63 and a beta of 0.61. argenx SE has a 1-year low of $327.73 and a 1-year high of $620.28.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same quarter last year, the firm posted ($1.25) EPS. On average, equities research analysts anticipate that argenx SE will post 2.2 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.